Oncotarget

Research Papers:

IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice

Mian Xie _, Xiao-jun Wu, Jin-jun Zhang and Chao-sheng He

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:32902-32913. https://doi.org/10.18632/oncotarget.5361

Metrics: PDF 1207 views  |   HTML 1402 views  |   ?  


Abstract

Mian Xie1,*, Xiao-jun Wu2,3,*, Jin-jun Zhang4, Chao-sheng He5,*

1China State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

2State Key Laboratory of Oncology in Southern China, Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China

3Collaborative Innovation Center of Cancer Medicine, Guangzhou, China

4Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

5Department of Internal Medicine, Guangdong General Hospital, Guangzhou, China

*These authors have contributed equally to this work

correspondence to:

Mian Xie, e-mail: mianxie@gird.cn

Keywords: lung cancer, IL13Rα2, TAZ, PI3K

Received: May 15, 2014     Accepted: September 08, 2015     Published: September 21, 2015

ABSTRACT

IL-13 receptor subunit alpha-2 (IL13Rα2) is associated with poor prognosis in some cancers. However, the role of IL13Rα2 in lung cancer remains unknown. We showed that IL13Rα2 overexpression was associated with late stages of disease progression and shorter disease-free survival (DFS) as well as overall survival (OS) in resected lung cancer patients. IL13Rα2 promoted the migration, invasion and anoikis resistance of lung cancer cells in vitro. Silencing of IL13Rα2 in lung cancer cells decreased invasion in vitro and lung metastasis in vivo. IL13Rα2 activated phosphatidylinositol 3 kinase (PI3K), Akt, and transcriptional coactivator with PDZ-binding motif (TAZ). Inhibition of PI3K attenuated activation of TAZ and its downstream target genes by IL13Rα2. We suggest that inhibition of IL13Rα2 is a potential therapeutic approach in lung cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5361